https://www.selleckchem.com/products/LBH-589.html
REC-2282is a novelhistone deacetylase inhibitorthat has shown antitumoractivity in in vitro and in vivo models of malignancy. The aims of this study were to characterize the population pharmacokinetics of REC-2282 (AR-42) from the first-in-human (NCT01129193) and phase I acute myeloid leukemia trials (NCT01798901) and to evaluate potential sources of variability. Additionally, we sought to understand alternate body size descriptors as sources of inter-individual variability (IIV), which was significant for dose-normalized maximum observ
Like
Comment
Share
